Search Immortality Topics:

Page 11234..1020..»

Category Archives: Pharmacogenomics

Pharmacogenomics (PGx) Market Research Report 2020: Key Players, Applications, Drivers, Trends and Forecast to 2026 – WaterCloud News


In addition, the report categorizes product type and end uses as dynamic market segments that directly impact the growth potential and roadmap of the target market. The report highlights the core developments that are common to all regional hubs and their subsequent impact on the holistic growth path of the Pharmacogenomics (PGx) market worldwide. Other valuable aspects of the report are the market development history, various marketing channels, supplier analysis, potential buyers and the analysis of the markets industrial chain.

Ask For Discounts @

Table of Content

1 Introduction of Pharmacogenomics (PGx) Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Pharmacogenomics (PGx) Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Pharmacogenomics (PGx) Market, By Deployment Model

5.1 Overview

6 Pharmacogenomics (PGx) Market, By Solution

6.1 Overview

7 Pharmacogenomics (PGx) Market, By Vertical

7.1 Overview

8 Pharmacogenomics (PGx) Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Pharmacogenomics (PGx) Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Customized Research Report Using Corporate Email Id @

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Pharmacogenomics (PGx) Market Size, Pharmacogenomics (PGx) Market Trends, Pharmacogenomics (PGx) Market Growth, Pharmacogenomics (PGx) Market Forecast, Pharmacogenomics (PGx) Market Analysis Sarkari result, Government Jobs, Sarkari naukri, NMK, Majhi Naukri,

View post:
Pharmacogenomics (PGx) Market Research Report 2020: Key Players, Applications, Drivers, Trends and Forecast to 2026 - WaterCloud News

Posted in Pharmacogenomics | Comments Off on Pharmacogenomics (PGx) Market Research Report 2020: Key Players, Applications, Drivers, Trends and Forecast to 2026 – WaterCloud News

Green Shield Canada invests in TELUS and TYDO backed GenXys – Private Capital Journal

Green Shield Canada (GSC) has made an investment in GenXys Health Care Systems Inc. Financial terms were not disclosed.

Vancouver based GenXys Health Care Systems is a provider of comprehensive precision prescribing software. GenXys precision prescribing software and pharmacogenetic solutions prevent adverse drug reactions, a leading cause of death in developed countries, and personalize drug selection to increase drug efficacy.

Green Shield Canada and GenXys will collaborate on new pharmacogenomics products set to launch later this year with a focus on driving more informed prescribing, fewer adverse drug reactions and better health outcomes for patients.

GenXys Health Care Systems is backed by Telus Ventures and Chinese incubator company JiuHui TYDO (), having raised $1.77 million seed funding in 2018.

photo credit: GenXys

News Release

Green Shield Canada invests in GenXys to harness power of pharmacogenomics

TORONTO, May 26, 2020 (GLOBE NEWSWIRE) With the concept of personalized medicine gathering momentum across the health care environment, Green Shield Canada (GSC) is pleased to announce an investment in GenXys, a Canadian pharmacogenomics leader, to leverage the value of tailoring drug treatment to a persons total health profile including their genetic makeup.

The two companies will be collaborating on new pharmacogenomics products set to launch later this year with a focus on driving more informed prescribing, fewer adverse drug reactions and better health outcomes for patients.

GenXys stood out as a forward-thinking partner that shared our commitment to solving complex health challenges, explains David Willows, GSCs EVP, Digital, Innovation and Brand Experience. GSC has a long history of measuring the value of health benefits spending, and we look forward to exploring the role of pharmacogenomics in maximizing patient health outcomes and advancing the specific value of drug spend.

We are excited to be working with the GSC team as we shape the next stages of the pharmacogenomics story, says Karl Pringle, GenXys CEO. Our partnership opens the door to a wide range of new possibilities.

This investment comes on the heels of a groundbreaking study conducted by GSC and HBM+ (its health benefit management solutions division) on the impact of pharmacogenomics on more than 200 outpatients who had been diagnosed with major mental health conditions, including depression and anxiety.

The full study results will be shared later this summer, but one key finding stands out those patients receiving pharmacogenomics-guided treatment reported significantly greater improvements over a six-month period across a range of clinical outcome measures, including severity of depression and anxiety as well as level of disability.

We had always felt that the key unanswered question was whether clinician access to pharmacogenetic test results would improve patient outcomes, adds Willows. This study clearly showed that it can, strengthening our belief in the impact of pharmacogenomics-guided treatments.

For more information:GSC Media Department1.800.268.6613 ext.

About Green Shield Canada (GSC)

GSC is Canadas fourth-largest health and dental benefits provider, and is uniquely structured as a social enterprise with the purpose of making it easier for people to live their healthiest lives. From coast-to-coast, our service delivery includes drug, dental, extended health care, vision, hospital, and travel benefits for groups and individuals, as well as administration and benefits management services. Supported by outcomes-based sustainability strategies, advanced technology, and exceptional customer service, GSC creates innovative programs for nearly four million plan participants nationwide.

Ted is the architect of CVCA infobase, and is the architectof CPE Media's, Canada's most sophisticated and advanced all private capital and public market financing database.

Green Shield Canada invests in TELUS and TYDO backed GenXys - Private Capital Journal

Posted in Pharmacogenomics | Comments Off on Green Shield Canada invests in TELUS and TYDO backed GenXys – Private Capital Journal

Global Pharmacogenomics (PGx) Market 2020 Future Analysis, Current Trends and Forecast with COVID-19 After Effects – Flagler Times

Global Pharmacogenomics (PGx) Market 2020 by Company, Type and Application, Forecast to 2025 is an analysis from is based on past information and future opportunities in the global market. The report covers many aspects of the industry like the market size, market status, market trends and forecast from 2020 to 2025. Information on the competitors and the specific growth opportunities with key market drivers has been provided. The report estimates revenue, production, consumption, sales, suppliers, manufacturers, countries, types, and applications. It also shows a regional growth status by analyzing all of the areas and worldwide locations of the global Pharmacogenomics (PGx) market covering market length, volume, and value, as well as price facts.

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.


The report also goes into the past for analyzing the market scenario, where it found various aspects such as segmentation, landscape analysis, developments, product types, and applications. All the key industry players are covered combined with their company profiles, size, production value, product specifications, capacity and 2020-2025 market shares occupied by each company. Additionally, their contact information, product specifications, company profiles, and production value has been provided. It represents a future outlook prospect on different factors driving or prohibiting global Pharmacogenomics (PGx) market growth.

The key companies in the global industry include- Abbott Laboratories , Myriad Genetics, Inc. , Astrazeneca , Affymetrix, Inc. , Laboratory Corporation of America Holdings , Assurex Health, Inc , Pfizer, Inc , Illumina, Inc. , GeneDX , Pathway Genomics , Transgenomic, Inc. , Qiagen, Inc. , Thermo Fisher Scientific , Rocheg , Teva Pharmaceutical Industries Ltd.

Segmentation by product type and analysis of the market: olymerase Chain Reaction (PCR), Microarray, Sequencing, Other, etc.

Segmentation by application and analysis of the market: ardiovascular Diseases (CVD), Central Nervous System (CNS), Cancer/Oncology, Infectious Diseases, Other, etc.

Analysis of The Regional Expanse:

Geographically the market report is divided into some major key regions, with sales data, revenue data (Million $$ USD), share data and growth rate of the industry for mentioned regions. This Pharmacogenomics (PGx) market report offers examination and growth of the market in these districts covering North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina, Colombia), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa).


Moreover, the report encompasses valuable advice and direction for businesses and individuals, estimating global Pharmacogenomics (PGx) market development trends, current market dynamics, upstream raw materials, and downstream demand. Overall report documents leading growth status, segmentation, landscape analysis, developments, product types, and applications.

There are 15 Chapters to Deeply Display the Global Pharmacogenomics (PGx) Market.

Chapter 1, to describe Pharmacogenomics (PGx) market introduction, product scope, market overview, market opportunities, market risk, market driving force;

Chapter 2, to track the top manufacturers with sales, revenue, and price in 2019 and 2020;

Chapter 3, to analyze the competitive situation among the top manufacturers, with sales, revenue, and market share in 2019 and 2020;

Chapter 4, to show the global market by regions, with sales, revenue, and market share of for each region, from 2015 to 2020;

Chapter 5, 6, 7, 8 and 9, to study the market by countries, by type, by application, and by manufacturers, with sales, revenue and market share by key countries in these regions;

Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2015 to 2020;

Chapter 12, market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025;

Chapter 13, 14 and 15, to assess sales channel, distributors, traders, dealers, research findings and Conclusion, appendix and data source

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team (, who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us is a fully dedicated global market research agency providing thorough quantitative and qualitative analysis of extensive market research.Our corporate is identified by recognition and enthusiasm for what it offers, which unites its staff across the world.We are desired market researchers proving a reliable source of extensive market analysis on which readers can rely on. Our research team consist of some of the best market researchers, sector and analysis executives in the nation, because of which is considered as one of the most vigorous market research enterprises. finds perfect solutions according to the requirements of research with considerations of content and methods. Unique and out of the box technologies, techniques and solutions are implemented all through the research reports.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: sales@researchstore.bizWeb:

Originally posted here:
Global Pharmacogenomics (PGx) Market 2020 Future Analysis, Current Trends and Forecast with COVID-19 After Effects - Flagler Times

Posted in Pharmacogenomics | Comments Off on Global Pharmacogenomics (PGx) Market 2020 Future Analysis, Current Trends and Forecast with COVID-19 After Effects – Flagler Times

GPs receive millions to further general practice – RACGP


Professor Jon Emery and Associate Professor Jason Ong speak to newsGP about their respective research.

Early cancer detection, pharmacogenomic testing for more effective antidepressant prescribing, HIV prevention.Two GPs have received sought-after grants to conduct research that has the potential to dramatically alter the way healthcare is provided, showing the scope of general practice.Among the recipients is Professor Jon Emery, GP and Herman Professor of Primary Care Cancer Research at the University of Melbourne and Western Health. He has been awarded a National Health and Medical Research Council (NHMRC) Investigator Grant of $2,360,520 for his project Transforming early detection of cancer in primary care.Over five years, the project will seek to transform approaches for the early detection of cancers in primary care through advances in computer-aided diagnosis and use of new genetic tests to identify patients at increased risk of cancer.We know that there are quite a few patients whose cancer diagnosis is delayed, and for a variety of reasons, Professor Emery told newsGP.Sometimes its by virtue of the nature of the complexity and vagueness of symptoms.Professor Emerys team will draw on data from existing electronic medical records to look at patterns of visits, test results and prescribing in order to develop sophisticated diagnostic algorithms for support tool Future Health Today, which identifies patients that GPs should consider for further investigation.The decision support tool is partly to flag patients who are returning with repeated, but subtle symptoms, Professor Emery said.But also, often abnormal test results are not always followed up and some are abnormal results that have only recently been identified as being associated with an increased risk of a cancer diagnosis.Probably the most interesting one is raised platelet count that we know is a marker of a number of cancers.The secondary aspect of the project will focus on using genomic testing to assess a patients risk of developing bowel cancer over 10 years to then tailor screening tests and prevention.That might prompt GPs to commence screening earlier, for example in their 40s, or potentially to delay screening because theyre actually at lower risk, Professor Emery explains.There are a number of polygenic risk scores for a number of other cancers, and well be gradually looking at how you might then start to implement a single test that would actually determine your risk.Professor Emery has also been named a recipient of one of 30 Medical Research Future Fund (MRFF) grants, for the sum of $1.39 million, to explore another aspect of genomics.His team will run a controlled clinical trial, investigating the effects of pharmacogenomics to prescribe antidepressants in primary care for patients with major depressive disorder.Its been known for some time that there are common genetic variants that determine the way we metabolise a number of different commonly prescribed drugs, Professor Emery said.Therefore that affects your responses either in terms of your risk of developing side effects or whether you actually require a larger dose to actually achieve the therapeutic response. Antidepressants are a good example of this.So [its] really looking at the impact of using pharmacogenomic tests to tailor both dosage and selection of antidepressant, and the impact that has on resolution of depressive symptoms.Associate Professor Jason Ong, a sexual health physician and post-doctoral research fellow at Monash University, was the other GP recipient of an NHMRC grant, receiving more than $1.5 million for his research project Leaving no one behind: community-driven approaches to eliminate HIV in Australia.While new HIV infections are declining in Australian-born men, he noted inequities within the statistics that showed numbers on the rise among overseas-born Australian men.A lot of times these people are still closeted, so they havent come out to their communities and even to GPs they may not identify themselves as gay or at risk for HIV, Associate Professor Ong told newsGP.So over the next five years, the project is looking at how we can better serve this group. How do we as the primary care workforce reach these people?He believes the missing link in HIV policy is direct community input, which he will seek to obtain through his project using the methodology of crowdsourcing.Its basically the idea of getting wisdom from the crowds. We get ideas from the affected community and then we develop those ideas rather than imposing certain policies, Associate Professor Ong explains.Through the project, he will also seek greater community involvement when it comes to testing for sexually transmitted diseases (STDs) through the application of a Pay It Forward system, which Associated Professor Ong successfully trialled in China.It usually costs about US$22 to do a test, which is very expensive for the Chinese. So we ran a trial where told patients You can actually test for STDs for free. Because someone cares for you, they paid for you. Then after theyve done the test, we give them the option Do you also want to pay it forward?, he said.The theory is that if it does work, it kind of goes viral and people just pay for each other.Ill be using activities like this, trying to get the community to also participate, rather than doctors just saying that you should do an HIV test.It was while working as a general practice registrar at a clinic focusing on sexual minorities that Associate Professor Ongs interest in sexual health developed.I never really thought about that as GP, but it certainly sparked some interest in how there are quite specific needs in that population, but also there are ways that GPs can provide that holistic care, he said.Thats the strength of a GP its not just talking about sexual health, its the holistic person, dealing with their mental health, substance use, and all sorts of things.In fact, HIV is not diagnosed by the specialists, its actually the GPs that diagnose most of the HIV cases in Australia. So theres a need to harness this workforce and also get them to think outside the box.While the majority of healthcare is delivered through general practice, with 84% of the population seeing a GP at least once each year, a much smaller proportion of NHMRC funding is allocated to GPs.As such, Professor Emery says GPs are well placed to provide even greater insights.We also need to be supporting other types of research. Maybe thats using existing data from general practice so that we really understand what contributes to high quality care where there are potential evidence gaps in the way that care is being provided, he said.That requires us to be supporting this concept of practice-based research networks.Log in below to join the conversation.

cancer general practice research HIV mental health NHMRC Investigator Grants sexual health

See the article here:
GPs receive millions to further general practice - RACGP

Posted in Pharmacogenomics | Comments Off on GPs receive millions to further general practice – RACGP

Global Cancer Molecular Biomarkers Market to Register Growth in Incremental Opportunity after COVID-19 pandemic and Forecast 2015 to 2021 – Cole of…

Cancer molecular biomarkers refer to naturally-occurring molecules or genes in living organisms, which is an indicator for the presence of cancer in the body. A biomarker is a measurable indicator of biological process, condition, or disease and can be found in the blood, tissues, or other body fluids. Cancer molecular biomarkers help to diagnose cancer and monitor patients responses to treatments. On the basis of diagnostics, the cancer molecular biomarkers market can be segmented into immunoassays, immunohistochemical (IHC) tests, genetic and genomic markers, proteomics, flow cytometry, stem cell markers, monoclonal antibodies, pharmacogenomics, DNA microarrays, and IVD multivariate index assays (IVDMIA).

To remain ahead of your competitors, request for a sample [emailprotected]

On the basis of discovery , the cancer molecular biomarkers market can be segmented into genetic methods, protein methods, and imaging. Genetic methods include DNA arrays, southern blot, polymerase chain reaction (PCR), fluorescent in situ hybridization (FISH), and reverse transcriptase polymerase chain reaction (RT-PCR). Protein methods include immunohistochemistry (IHC) and mass spectrometry (MS). Imaging methods include positron emission tomography (PET), computed tomography (CT), magnetic resonance spectroscopy (MRS), x-ray, ultrasound, magnetic resonance imaging (MRI), and biophotonics.

North America has the largest market for cancer molecular biomarkers due to the growing IT industry, technological advancements, rise in the incidences of cancer, growing spending from government and private healthcare organizations, and improved healthcare infrastructure in this region.The North America market for cancer molecular biomarkers is followed by Europe. Asia is expected to witness high growth rate in thecancer molecular biomarkers market in the next few years due toincreasing research and development activities, rise in government intervention, growing awareness regarding cancer molecular biomarkers, and improving healthcare infrastructurein the region.

How the Coronavirus Threat has Taken Global Business into Uncharted Waters

Factors such as technological advancements, increasing research and development activities, increase in funding from various government and non-government organizations, rise in healthcare expenditure, non invasive technology, increasing incidences of cancer, and streamlined drug delivery process are expected to drive the market for cancer molecular biomarkers .In addition, growing survival rates and increased accuracy of diagnosis with the help of biomarkers are expected to drive market for cancer molecular biomarkers. However, issues related to reimbursement, high cost of diagnosis, requirement of immediate processing , lack of awareness, and various validation issues aresome of the major factors restraining growth of the globalcancer molecular biomarkers market.

Growing populationand economies in developing countries such as India and China is expected to drive growth of thecancer molecular biomarkers market in Asia. In addition,despite high cost involved in R&D, pharmaceutical companies are showing increased interest in this field and innovations along with technological advancement such as emergence of genetic based in vitro diagnostics, enhanced therapeutic effectiveness and decrease in the severity of the adverse effects are expected to offer new opportunities for global cancer molecular biomarkers market .

To receive extensive list of important regions, ask for TOC here @

Increasing number of mergers and acquisitions, risingnumber of collaborations, and product launches are some of the latest trends in the global cancer molecular biomarkers market.

Some of the major companies operating in the global cancer molecular biomarkers market are ,

For in-depth competitive analysis, Check Pre-Book here @

Key geographies evaluated in this report are:

Key features of this report

Go here to see the original:
Global Cancer Molecular Biomarkers Market to Register Growth in Incremental Opportunity after COVID-19 pandemic and Forecast 2015 to 2021 - Cole of...

Posted in Pharmacogenomics | Comments Off on Global Cancer Molecular Biomarkers Market to Register Growth in Incremental Opportunity after COVID-19 pandemic and Forecast 2015 to 2021 – Cole of…

The Economic Impact of Coronavirus on The Leading Companies Competing in the Pharmacogenomic (PGx) Testing Market: Industry Forecast, 2018 to 2028 -…

COVID-19 Analysis on the Global Pharmacogenomic (PGx) Testing Market

A recent market research report on the Pharmacogenomic (PGx) Testing market published by Fact.MR is an in-depth assessment of the current landscape of the market. Further, the report elaborates on the impact of the COVID-19 on the Pharmacogenomic (PGx) Testing market and provides a thorough understanding of the growth potential of each market segment over the forecast period (2020-2030).

According to the analyst at Fact.MR, the Pharmacogenomic (PGx) Testing market is evenly slated to register a CAGR growth of ~XX% during the assessment period and attain a value of ~US$ XX by the end of 2030. The report analyzes the micro and macro-economic factors that are projected to impact the growth of the Pharmacogenomic (PGx) Testing market in the upcoming years. Further, a detailed analysis of the business continuity strategies of leading market participants is enclosed in the presented report.

Request Sample Report @

Key Insights Enclosed in the Report

Segmentation of the Pharmacogenomic (PGx) Testing Market

The presented report dissects the Pharmacogenomic (PGx) Testing market into different segments and ponders over the current and future prospects of each segment. The report depicts the year-on-year growth of each segment and touches upon the different factors that are likely to influence the growth of each market segment. Further, projections are made taking into account the impact of the COVID-19 pandemic on the each market segment.

The various segments of the Pharmacogenomic (PGx) Testing market analyzed in the report include:

Competitive landscape

Request Methodology On This Report @

Important doubts related to the Pharmacogenomic (PGx) Testing market clarified in the report:

Why Choose Fact.MR

Ask analyst about this report at

Continue reading here:
The Economic Impact of Coronavirus on The Leading Companies Competing in the Pharmacogenomic (PGx) Testing Market: Industry Forecast, 2018 to 2028 -...

Posted in Pharmacogenomics | Comments Off on The Economic Impact of Coronavirus on The Leading Companies Competing in the Pharmacogenomic (PGx) Testing Market: Industry Forecast, 2018 to 2028 -…